Stammdaten
Enliven Therapeutics, Inc., ein Biopharmazeutika-Unternehmen im klinischen Stadium, konzentriert sich auf die Entdeckung und Entwicklung von Kleinmolekül-Inhibitoren für Krebspatienten. Seine Pipeline von Kleinmolekül-Kinase-Inhibitoren umfasst ELVN-001, das in einer Phase-1-Studie bei Erwachsenen mit chronischer myeloischer Leukämie evaluiert wird, und ELVN-002, für das eine Phase-1-Studie zur Evaluierung bei Patienten mit Krebserkrankungen mit abnormaler HER2-Expression aktiviert wurde. Das Unternehmen ist in Boulder, Colorado ansässig. KI
Unternehmen & Branche
| Name | Enliven Therapeutics, Inc. |
|---|---|
| Ticker | ELVN |
| CIK | 0001672619 |
| Börse | Nasdaq |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | 29337E102 |
|---|---|
| ISIN | US29337E1029 |
| Typ | Common Stock |
| Marktkapitalisierung | 3,07 Mrd. USD |
| Beta | 0,29 |
Sitz & Kontakt
| Sitz (Inkorporation) | DE |
|---|---|
| Geschäftsadresse | 205 PARK ROAD, 94010 BURLINGAME, CA |
| Telefon | 650-547-5814 |
| EIN (IRS) | 81-1523849 |
Listing & Historie
| Listing-Börsen | Nasdaq |
|---|---|
| Fiskaljahr-Ende | 31.12. |
| SEC-Filer-Status | Non-accelerated filer |
| Frühere Namen | IMARA Inc. (bis 2023) |
Bewertung
| KBV (P/B) | 6,68 |
|---|---|
| FCF-Rendite | -2,3 % vs. -19,8 % (2021) ▲ |
Qualität & Bilanz
| ROIC | -22,5 % |
|---|
Basis: SEC-XBRL-Jahresabschluss bis 31.12.2025, Multiples mit aktueller Marktkapitalisierung (trailing), Vergleich: GJ bis 2021. Kennzahlen erklärt →
Kennzahlen-Historie (5 Jahre) – Tabelle & Verlauf
| Kennzahl | 2021 | 2022 | 2023 | 2024 | 2025 | TTM* | Verlauf |
|---|---|---|---|---|---|---|---|
| Bewertung | |||||||
| KBV (P/B) | – | – | 2,32 | 3,55 | 1,99 | 6,77 | |
| FCF-Rendite | -19,8 % | -54,9 % | -10,7 % | -6,6 % | -7,7 % | -2,1 % | |
| Qualität & Bilanz | |||||||
| ROIC | – | – | -29,1 % | -28,7 % | -22,5 % | -21,8 % | |
Basis: SEC-XBRL-Jahresabschlüsse, Multiples je Geschäftsjahr mit Marktkapitalisierung zum Bilanzstichtag (point-in-time).
TTM* = letzte zwölf Monate (vorläufig, ungeprüft): jüngstes Geschäftsjahr + laufendes YTD − Vorjahres-YTD aus den Quartalsberichten (10-Q); Bewertungs-Multiples gegen die aktuelle Marktkapitalisierung. Kein testierter Jahresabschluss.
Externe Quelle:
SEC EDGAR »
Externe Links: Yahoo Finance » · OnVista »
Glück Conviction Score™ ⓘ
ⓘ
ELVN
Enliven Therapeutics, Inc.
Effektiv
Schwach
Handelsvolumen
Mittel
Insider
0,0
Keine Insider-Käufe
Institutionell
69,9
65 neu, 60 erhöht, 1441,3M $ netto
Aktivist
27,4
Kein 13D/13G
Risikofreier Zins (T-Bills): 3,71% (Stand: 30.06.2026)
Score-Verlauf (90 Tage)
Konviktions-Verlauf — oben stark · Mitte neutral · unten schwach
Farbzonen = Stärkestufen (Sehr schwach … Sehr stark). Exit-Score unter der Schwelle = Timing-Ausstieg. Komponenten per Legende einblenden.
Kursverlauf (24 Monate)
Indexierte Darstellung (Start = 100) — die Kursform bleibt sichtbar, absolute Kurse sind angemeldeten Mitgliedern vorbehalten.
Technische Indikatoren
Technical-Score basiert auf 12 Indikatoren (Trend, Momentum, Volatilität, Position) mit fixen Gewichten — wird aktuell nur informativ angezeigt und fließt nicht in den Glück Conviction Score ein. Integration nach Backtest-Kalibrierung (P5).
| Indikator | Signal | Gewicht | Wert | Detail | Beitrag |
|---|---|---|---|---|---|
| Kurs vs SMA50 | Bullisch | 10 % | 44.60 | +21.8 % vs SMA50 | |
| Kurs vs SMA200 | Bullisch | 15 % | 31.48 | +72.6 % vs SMA200 | |
| EMA20 vs EMA50 | Bullisch | 5 % | 50.17 | EMA50: 46.07 | |
| MACD-Histogramm | Bärisch | 10 % | -0.053 | Bearisch | |
| RSI(14) | Neutral | 10 % | 64.6 | Neutral (30–70) | |
| Stoch %K(14) | Bärisch | 5 % | 92.6 | Überkauft | |
| ADX(14)+DI | Bullisch | 10 % | 34.1 | +DI: 23.3 / −DI: 11.2 | |
| Z-Score(60) | Bärisch | 5 % | 1.88 | Extrem überkauft | |
| 52W-Position | Bullisch | 5 % | 100.0 % | Hoch 54.33 / Tief 15.14 | |
| Bollinger(20,2σ) | Bärisch | 5 % | 105.1 % | Upper 54.01 / Mid 50.83 / Lower 47.65 | |
| LinReg-Slope(60) | Bullisch | 10 % | +0.2144 | R²=0.47 / annualisiert +122.2 % |
Insider-Transaktionen (12 Monate) ⓘ
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-07-17 | Collins Helen Louise | Officer, CHIEF MEDICAL OFFICER | Open Market Sale | -63 | 53,92 | -3.397,01 | -0,4% | |
| 2026-07-17 | Hohl Benjamin | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -2.638 | 53,38 | -140.823,04 | -17,8% | |
| 2026-07-17 | Hohl Benjamin | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -369 | 51,48 | -18.996,97 | -2,4% | |
| 2026-07-17 | Hohl Benjamin | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -2.564 | 52,32 | -134.143,35 | -17,0% | |
| 2026-07-17 | Hohl Benjamin | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -324 | 49,97 | -16.190,77 | -2,0% | |
| 2026-07-17 | Hohl Benjamin | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -123 | 53,87 | -6.626,21 | -0,8% | |
| 2026-07-17 | Collins Helen Louise | Officer, CHIEF MEDICAL OFFICER | Open Market Sale | -2.184 | 53,42 | -116.669,06 | -14,8% | |
| 2026-07-17 | Collins Helen Louise | Officer, CHIEF MEDICAL OFFICER | Open Market Sale | -2.063 | 52,39 | -108.084,90 | -13,7% | |
| 2026-07-17 | Collins Helen Louise | Officer, CHIEF MEDICAL OFFICER | Open Market Sale | -459 | 51,55 | -23.659,89 | -3,0% | |
| 2026-07-17 | Collins Helen Louise | Officer, CHIEF MEDICAL OFFICER | Open Market Sale | -231 | 50,05 | -11.562,52 | -1,5% | |
| 2026-07-06 | Kunkel Lori Anne | Director | Open Market Sale | -5.889 | 50,84 | -299.421,49 | -37,9% | |
| 2026-07-06 | Kunkel Lori Anne | Director | Open Market Sale | -4.111 | 49,98 | -205.481,76 | -26,0% | |
| 2026-06-22 | ORBIMED ADVISORS LLC | 10% Owner | Open Market Sale | -24.846 | 45,38 | -1.127.511,48 | -142,6% | |
| 2026-06-22 | ORBIMED ADVISORS LLC | 10% Owner | Open Market Sale | -787.024 | 45,38 | -35.715.149,12 | -4518,2% | |
| 2026-06-22 | ORBIMED ADVISORS LLC | 10% Owner | Open Market Sale | -46.776 | 45,00 | -2.104.920,00 | -266,3% | |
| 2026-06-22 | ORBIMED ADVISORS LLC | 10% Owner | Open Market Sale | -1.477 | 45,00 | -66.465,00 | -8,4% | |
| 2026-06-17 | Collins Helen Louise | Officer, CHIEF MEDICAL OFFICER | Open Market Sale | -2.599 | 43,87 | -114.018,39 | -14,4% | |
| 2026-06-17 | Hohl Benjamin | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -3.401 | 43,86 | -149.179,42 | -18,9% | |
| 2026-06-17 | Hohl Benjamin | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -1.379 | 42,79 | -59.000,52 | -7,5% | |
| 2026-06-17 | Hohl Benjamin | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -1.238 | 44,75 | -55.397,41 | -7,0% | |
| 2026-06-17 | Collins Helen Louise | Officer, CHIEF MEDICAL OFFICER | Open Market Sale | -1.268 | 42,83 | -54.304,64 | -6,9% | |
| 2026-06-17 | Collins Helen Louise | Officer, CHIEF MEDICAL OFFICER | Open Market Sale | -1.133 | 44,74 | -50.693,82 | -6,4% | |
| 2026-06-15 | ORBIMED ADVISORS LLC | 10% Owner | Open Market Sale | -272.322 | 45,02 | -12.259.936,44 | -1551,0% | |
| 2026-06-15 | ORBIMED ADVISORS LLC | 10% Owner | Open Market Sale | -9.086 | 45,02 | -409.051,72 | -51,7% | |
| 2026-06-05 | Kunkel Lori Anne | Director | Open Market Sale | -354 | 35,82 | -12.679,82 | -1,6% | |
| 2026-06-05 | Kunkel Lori Anne | Director | Open Market Sale | -7.779 | 34,28 | -266.659,45 | -33,7% | |
| 2026-06-05 | Kunkel Lori Anne | Director | Open Market Sale | -1.867 | 35,36 | -66.012,08 | -8,4% | |
| 2026-05-18 | Collins Helen Louise | Officer, CHIEF MEDICAL OFFICER | Open Market Sale | -1.302 | 40,25 | -52.401,98 | -6,6% | |
| 2026-05-18 | Collins Helen Louise | Officer, CHIEF MEDICAL OFFICER | Open Market Sale | -3.475 | 39,53 | -137.380,65 | -17,4% | |
| 2026-05-18 | Collins Helen Louise | Officer, CHIEF MEDICAL OFFICER | Open Market Sale | -223 | 41,21 | -9.188,76 | -1,2% | |
| 2026-04-17 | Collins Helen Louise | Officer, CHIEF MEDICAL OFFICER | Open Market Sale | -140 | 45,81 | -6.413,50 | -0,8% | |
| 2026-04-17 | Collins Helen Louise | Officer, CHIEF MEDICAL OFFICER | Open Market Sale | -2.441 | 48,06 | -117.303,48 | -14,8% | |
| 2026-04-17 | Collins Helen Louise | Officer, CHIEF MEDICAL OFFICER | Open Market Sale | -2.419 | 47,39 | -114.635,44 | -14,5% | |
| 2026-03-25 | Collins Helen Louise | Officer, CHIEF MEDICAL OFFICER | Open Market Sale | -40.000 | 35,10 | -1.404.024,00 | -177,6% | |
| 2026-03-17 | Collins Helen Louise | Officer, CHIEF MEDICAL OFFICER | Open Market Sale | -5.000 | 27,76 | -138.800,00 | -17,6% | |
| 2026-03-10 | Collins Helen Louise | Officer, CHIEF MEDICAL OFFICER | Open Market Sale | -10.129 | 30,19 | -305.826,92 | -38,7% | |
| 2026-03-09 | Collins Helen Louise | Officer, CHIEF MEDICAL OFFICER | Open Market Sale | -29.871 | 30,02 | -896.811,06 | -113,5% | |
| 2026-03-06 | Hohl Benjamin | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -10.000 | 29,58 | -295.839,00 | -37,4% | |
| 2026-02-17 | Collins Helen Louise | Officer, CHIEF MEDICAL OFFICER | Open Market Sale | -45.000 | 26,17 | -1.177.861,50 | -149,0% | |
| 2026-02-17 | Heyman Richard A. | Director | Open Market Sale | -1.230 | 26,18 | -32.196,36 | -4,1% | |
| 2026-02-06 | Lyssikatos Joseph P | Officer, CHIEF SCIENTIFIC OFFICER | Open Market Sale | -5.000 | 29,04 | -145.219,00 | -18,4% | |
| 2026-01-20 | Lyssikatos Joseph P | Officer, CHIEF SCIENTIFIC OFFICER | Open Market Sale | -5.491 | 26,37 | -144.814,14 | -18,3% | |
| 2026-01-20 | Heyman Richard A. | Director | Open Market Sale | -512 | 26,46 | -13.547,11 | -1,7% | |
| 2026-01-20 | Heyman Richard A. | Director | Open Market Sale | -718 | 26,96 | -19.354,41 | -2,4% | |
| 2026-01-20 | Lyssikatos Joseph P | Officer, CHIEF SCIENTIFIC OFFICER | Open Market Sale | -14.509 | 26,90 | -390.284,85 | -49,4% | |
| 2026-01-09 | Patel Anish | Officer, CHIEF OPERATING OFFICER | Open Market Sale | -48.057 | 27,98 | -1.344.836,70 | -170,1% | |
| 2026-01-09 | Patel Anish | Officer, CHIEF OPERATING OFFICER | Open Market Sale | -243 | 28,50 | -6.925,50 | -0,9% | |
| 2026-01-09 | Heyman Richard A. | Director | Open Market Sale | -4.285 | 25,00 | -107.125,43 | -13,6% | |
| 2026-01-09 | Lyssikatos Joseph P | Officer, CHIEF SCIENTIFIC OFFICER | Open Market Sale | -50.000 | 29,13 | -1.456.715,00 | -184,3% | |
| 2026-01-09 | Lyssikatos Joseph P | Officer, CHIEF SCIENTIFIC OFFICER | Open Market Sale | -41.198 | 24,90 | -1.025.863,16 | -129,8% | |
| 2026-01-08 | Heyman Richard A. | Director | Open Market Sale | -1.620 | 25,00 | -40.500,00 | -5,1% | |
| 2026-01-08 | Lyssikatos Joseph P | Officer, CHIEF SCIENTIFIC OFFICER | Open Market Sale | -33.802 | 24,92 | -842.474,29 | -106,6% | |
| 2026-01-08 | Lyssikatos Joseph P | Officer, CHIEF SCIENTIFIC OFFICER | Open Market Sale | -7.500 | 20,13 | -150.961,50 | -19,1% | |
| 2026-01-08 | Heyman Richard A. | Director | Open Market Sale | -8.015 | 25,04 | -200.655,53 | -25,4% | |
| 2025-12-19 | Lyssikatos Joseph P | Officer, CHIEF SCIENTIFIC OFFICER | Open Market Sale | -5.000 | 16,84 | -84.206,00 | -10,7% | |
| 2025-12-08 | Patel Anish | Officer, CHIEF OPERATING OFFICER | Open Market Sale | -4.958 | 20,76 | -102.938,99 | -13,0% | |
| 2025-12-08 | Patel Anish | Officer, CHIEF OPERATING OFFICER | Open Market Sale | -1.705 | 21,78 | -37.133,88 | -4,7% | |
| 2025-11-19 | Lyssikatos Joseph P | Officer, CHIEF SCIENTIFIC OFFICER | Open Market Sale | -492 | 23,09 | -11.360,77 | -1,4% | |
| 2025-11-19 | Lyssikatos Joseph P | Officer, CHIEF SCIENTIFIC OFFICER | Open Market Sale | -12.008 | 22,30 | -267.794,01 | -33,9% | |
| 2025-11-17 | Kintz Samuel | Director, Officer, PRESIDENT AND CEO | Open Market Sale | -12.500 | 21,82 | -272.738,75 | -34,5% | |
| 2025-11-07 | Patel Anish | Officer, CHIEF OPERATING OFFICER | Open Market Sale | -6.054 | 17,35 | -105.038,72 | -13,3% | |
| 2025-11-07 | Patel Anish | Officer, CHIEF OPERATING OFFICER | Open Market Sale | -613 | 17,94 | -10.995,44 | -1,4% | |
| 2025-10-20 | Lyssikatos Joseph P | Officer, CHIEF SCIENTIFIC OFFICER | Open Market Sale | -12.500 | 22,08 | -276.025,00 | -34,9% | |
| 2025-10-17 | Kintz Samuel | Director, Officer, PRESIDENT AND CEO | Open Market Sale | -12.500 | 21,33 | -266.653,75 | -33,7% | |
| 2025-10-07 | Patel Anish | Officer, CHIEF OPERATING OFFICER | Open Market Sale | -6.667 | 20,10 | -133.992,70 | -17,0% | |
| 2025-09-29 | Hohl Benjamin | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -3.250 | 20,40 | -66.291,23 | -8,4% | |
| 2025-09-26 | Kintz Samuel | Director, Officer, PRESIDENT AND CEO | Open Market Sale | -3.700 | 20,06 | -74.227,55 | -9,4% | |
| 2025-09-26 | Lyssikatos Joseph P | Officer, CHIEF SCIENTIFIC OFFICER | Open Market Sale | -4.000 | 20,25 | -81.005,20 | -10,2% | |
| 2025-09-23 | Lyssikatos Joseph P | Officer, CHIEF SCIENTIFIC OFFICER | Open Market Sale | -1.500 | 20,03 | -30.045,00 | -3,8% | |
| 2025-09-23 | Kintz Samuel | Director, Officer, PRESIDENT AND CEO | Open Market Sale | -2.800 | 20,03 | -56.084,00 | -7,1% | |
| 2025-09-19 | Kintz Samuel | Director, Officer, PRESIDENT AND CEO | Open Market Sale | -1.000 | 20,25 | -20.250,00 | -2,6% | |
| 2025-09-19 | Lyssikatos Joseph P | Officer, CHIEF SCIENTIFIC OFFICER | Open Market Sale | -4.870 | 19,11 | -93.063,27 | -11,8% | |
| 2025-09-19 | Lyssikatos Joseph P | Officer, CHIEF SCIENTIFIC OFFICER | Open Market Sale | -2.130 | 20,02 | -42.634,08 | -5,4% | |
| 2025-09-17 | Kintz Samuel | Director, Officer, PRESIDENT AND CEO | Open Market Sale | -5.000 | 19,09 | -95.473,00 | -12,1% | |
| 2025-09-08 | Patel Anish | Officer, CHIEF OPERATING OFFICER | Open Market Sale | -6.667 | 20,24 | -134.957,41 | -17,1% | |
| 2025-08-27 | Hohl Benjamin | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -3.250 | 20,63 | -67.038,73 | -8,5% | |
| 2025-08-21 | Lyssikatos Joseph P | Officer, CHIEF SCIENTIFIC OFFICER | Open Market Sale | -7.500 | 20,01 | -150.099,00 | -19,0% | |
| 2025-08-20 | Kintz Samuel | Director, Officer, PRESIDENT AND CEO | Open Market Sale | -1.517 | 20,00 | -30.343,49 | -3,8% | |
| 2025-08-19 | Kintz Samuel | Director, Officer, PRESIDENT AND CEO | Open Market Sale | -590 | 20,00 | -11.800,00 | -1,5% | |
| 2025-08-19 | Lyssikatos Joseph P | Officer, CHIEF SCIENTIFIC OFFICER | Open Market Sale | -5.000 | 19,62 | -98.117,50 | -12,4% | |
| 2025-08-18 | Kintz Samuel | Director, Officer, PRESIDENT AND CEO | Open Market Sale | -10.393 | 20,02 | -208.106,31 | -26,3% | |
| 2025-08-07 | Patel Anish | Officer, CHIEF OPERATING OFFICER | Open Market Sale | -6.262 | 18,20 | -113.948,99 | -14,4% | |
| 2025-08-07 | Patel Anish | Officer, CHIEF OPERATING OFFICER | Open Market Sale | -405 | 18,93 | -7.666,53 | -1,0% | |
| 2025-07-28 | Hohl Benjamin | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -3.185 | 20,45 | -65.119,24 | -8,2% | |
| 2025-07-28 | Hohl Benjamin | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -65 | 21,30 | -1.384,52 | -0,2% |
Fondsaktivität (Vorquartalsvergleich) ⓘ
⚠ Vorläufige Daten: Erst 1932 von typischerweise 8378 Fonds (23 %) haben für das aktuelle 13F-Quartal eingereicht — Werte können sich in den kommenden Wochen noch deutlich ändern.
| Fonds | Aktuell (Stk) | Vorquartal (Stk) | Veränderung (Stk) | Wert (USD) | Status | Δ | Trend |
|---|---|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC | 7.959.538 | 0 | 7.959.538 | 312.013.890 | Neu | +100,0% | |
| FMR LLC | 6.829.246 | 0 | 6.829.246 | 267.706.443 | Neu | +100,0% | |
| Polar Capital Holdings Plc | 5.065.933 | 0 | 5.065.933 | 198.584.574 | Neu | +100,0% | |
| BlackRock, Inc. | 3.684.707 | 0 | 3.684.707 | 144.440.514 | Neu | +100,0% | |
| Commodore Capital LP | 3.275.000 | 0 | 3.275.000 | 128.380.000 | Neu | +100,0% | |
| Vestal Point Capital, LP | 3.250.000 | 0 | 3.250.000 | 127.400.000 | Neu | +100,0% | |
| Bellevue Group AG | 2.320.867 | 0 | 2.320.867 | 90.977.986 | Neu | +100,0% | |
| CITADEL ADVISORS LLC | 1.871.515 | 0 | 1.871.515 | 73.363.388 | Neu | +100,0% | |
| Fairmount Funds Management LLC | 1.855.644 | 0 | 1.855.644 | 72.741.245 | Neu | +100,0% | |
| Venrock Adviser, LLC | 1.726.331 | 0 | 1.726.331 | 67.672.175 | Neu | +100,0% | |
| Novo Holdings A/S | 1.280.000 | 0 | 1.280.000 | 50.176.000 | Neu | +100,0% | |
| STATE STREET CORP | 1.091.106 | 0 | 1.091.106 | 42.771.355 | Neu | +100,0% | |
| GEODE CAPITAL MANAGEMENT, LLC | 1.066.420 | 0 | 1.066.420 | 41.813.049 | Neu | +100,0% | |
| Logos Global Management LP | 1.040.000 | 0 | 1.040.000 | 40.768.000 | Neu | +100,0% | |
| Caption Management, LLC | 956.500 | 0 | 956.500 | 37.494.800 | Neu | +100,0% | |
| Pictet Asset Management Holding SA | 929.544 | 0 | 929.544 | 36.438.125 | Neu | +100,0% | |
| BAKER BROS. ADVISORS LP | 905.191 | 0 | 905.191 | 35.483.487 | Neu | +100,0% | |
| Rock Springs Capital Management LP | 826.500 | 0 | 826.500 | 32.398.800 | Neu | +100,0% | |
| Siren, L.L.C. | 746.226 | 0 | 746.226 | 29.252.059 | Neu | +100,0% | |
| DIMENSIONAL FUND ADVISORS LP | 681.715 | 0 | 681.715 | 26.714.134 | Neu | +100,0% | |
| First Turn Management, LLC | 623.839 | 0 | 623.839 | 24.454.489 | Neu | +100,0% | |
| Candriam S.C.A. | 594.079 | 0 | 594.079 | 23.287.897 | Neu | +100,0% | |
| Jones Hill Capital LP | 593.040 | 0 | 593.040 | 23.247.168 | Neu | +100,0% | |
| Affinity Asset Advisors, LLC | 586.904 | 0 | 586.904 | 23.006.637 | Neu | +100,0% | |
| MORGAN STANLEY | 518.572 | 0 | 518.572 | 20.328.037 | Neu | +100,0% | |
| GOLDMAN SACHS GROUP INC | 473.115 | 0 | 473.115 | 18.546.108 | Neu | +100,0% | |
| Avidity Partners Management LP | 400.000 | 0 | 400.000 | 15.680.000 | Neu | +100,0% | |
| Assenagon Asset Management S.A. | 306.574 | 0 | 306.574 | 15.558.631 | Neu | +100,0% | |
| NORTHERN TRUST CORP | 372.316 | 0 | 372.316 | 14.594.788 | Neu | +100,0% | |
| Capricorn Fund Managers Ltd | 369.400 | 0 | 369.400 | 14.480.480 | Neu | +100,0% | |
| STEMPOINT CAPITAL LP | 363.438 | 0 | 363.438 | 14.246.770 | Neu | +100,0% | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 360.577 | 0 | 360.577 | 14.134.618 | Neu | +100,0% | |
| MILLENNIUM MANAGEMENT LLC | 345.318 | 0 | 345.318 | 13.536.466 | Neu | +100,0% | |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 330.964 | 0 | 330.964 | 12.973.789 | Neu | +100,0% | |
| ADAR1 Capital Management, LLC | 329.540 | 0 | 329.540 | 12.917.968 | Neu | +100,0% | |
| Spruce Street Capital LP | 329.006 | 0 | 329.006 | 12.897.035 | Neu | +100,0% | |
| VANGUARD FIDUCIARY TRUST CO | 312.763 | 0 | 312.763 | 12.260.310 | Neu | +100,0% | |
| BALYASNY ASSET MANAGEMENT L.P. | 310.025 | 0 | 310.025 | 12.152.980 | Neu | +100,0% | |
| JENNISON ASSOCIATES LLC | 309.180 | 0 | 309.180 | 12.119.856 | Neu | +100,0% | |
| ALLIANCEBERNSTEIN L.P. | 771.885 | 0 | 771.885 | 11.887.029 | Neu | +100,0% | |
| Woodline Partners LP | 301.673 | 0 | 301.673 | 11.825.582 | Neu | +100,0% | |
| UBS Group AG | 283.544 | 0 | 283.544 | 11.114.925 | Neu | +100,0% | |
| Seven Fleet Capital Management LP | 259.283 | 0 | 259.283 | 10.163.894 | Neu | +100,0% | |
| JANE STREET GROUP, LLC | 246.319 | 0 | 246.319 | 9.655.706 | Neu | +100,0% | |
| Soleus Capital Management, L.P. | 230.869 | 0 | 230.869 | 9.050.065 | Neu | +100,0% | |
| Exome Asset Management LLC | 220.091 | 0 | 220.091 | 8.627.567 | Neu | +100,0% | |
| Schonfeld Strategic Advisors LLC | 218.867 | 0 | 218.867 | 8.579.586 | Neu | +100,0% | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 206.572 | 0 | 206.572 | 8.097.622 | Neu | +100,0% | |
| First Light Asset Management, LLC | 201.867 | 0 | 201.867 | 7.913.186 | Neu | +100,0% | |
| Patient Square Capital LP | 200.000 | 0 | 200.000 | 7.840.000 | Neu | +100,0% |
Top-Fondshalter (Stand: 30.06.2026) ⓘ
⚠ Vorläufige Daten: Erst 1932 von typischerweise 8378 Fonds (23 %) haben für dieses Quartal eingereicht. Vollständigkeit erwartet bis 14.08.2026. Auswertungen (NEW/INC/DEC) sind noch zu konservativ — viele Spätfiler erscheinen aktuell als „Exits".
| Fonds | Anteile | Vorquartal (Stk) | Δ | Wert (USD) | Anteil (%) | Stimmkontrolle | Verlauf |
|---|---|---|---|---|---|---|---|
| Assenagon Asset Management S.A. | 306.574 | 0 | +100,0% | 15.558.631 | 80,72 | 100 % | 1 Q |
| TEMA ETFS LLC | 60.694 | 43.056 | +41,0% | 3.080.221 | 15,98 | 100 % | 5 Q |
| PSP Research LLC | 7.000 | 7.000 | 0,0% | 355.250 | 1,84 | 0 % | 2 Q |
| Mirae Asset Global Investments Co., Ltd. | 2.724 | 3.096 | -12,0% | 138.243 | 0,72 | 100 % | 12 Q |
| Versant Capital Management, Inc | 1.581 | 1.575 | +0,4% | 80.236 | 0,42 | 100 % | 8 Q |
| Farther Finance Advisors, LLC | 784 | 810 | -3,2% | 39.850 | 0,21 | 0 % | 11 Q |
| GAMMA Investing LLC | 228 | 222 | +2,7% | 11.571 | 0,06 | 100 % | 11 Q |
| MassMutual Private Wealth & Trust, FSB | 208 | 208 | 0,0% | 10.556 | 0,05 | 100 % | 6 Q |
| Handelsbanken Fonder AB | 17.300 | 0 | +100,0% | 878 | 0,00 | 0 % | 1 Q |
| FNY Investment Advisers, LLC | 2.500 | 0 | +100,0% | 126 | 0,00 | 100 % | 1 Q |
Halter-Trend (6 Quartale)
| Periode | Status | Halter | Anteile (Mio) | Wert (Mio $) |
|---|---|---|---|---|
| 30.06.2026 | vorl. | 10 | 0,4 | 19 |
| 31.03.2026 | ✓ | 169 | 63,9 | 2.485 |
| 31.12.2025 | ✓ | 125 | 63,4 | 15.668 |
| 30.09.2025 | ✓ | 133 | 59,7 | 28.204 |
| 30.06.2025 | ✓ | 123 | 59,6 | 27.636 |
| 31.03.2025 | ✓ | 118 | 51,5 | 15.995 |
Top 10 Neueinsteiger
| Fonds | Anteile | Wert (USD) |
|---|---|---|
| Bellevue Group AG | 2.320.867 | 90.977.986 |
| Siren, L.L.C. | 746.226 | 29.252.059 |
| First Turn Management, LLC | 623.839 | 24.454.489 |
| Jones Hill Capital LP | 593.040 | 23.247.168 |
| Affinity Asset Advisors, LLC | 586.904 | 23.006.637 |
| Caption Management, LLC | 370.000 | 14.504.000 |
| Capricorn Fund Managers Ltd | 369.400 | 14.480.480 |
| STEMPOINT CAPITAL LP | 363.438 | 14.246.770 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 330.964 | 12.973.789 |
| VANGUARD FIDUCIARY TRUST CO | 312.763 | 12.260.310 |
Top 10 Aufstocker
| Fonds | Anteile | Δ Anteile | Δ % | Wert (USD) |
|---|---|---|---|---|
| Polar Capital Holdings Plc | 5.065.933 | 1.552.253 | +44.2 % | 198.584.574 |
| ALLIANCEBERNSTEIN L.P. | 771.885 | 735.045 | +1995.2 % | 11.887.029 |
| BAKER BROS. ADVISORS LP | 905.191 | 633.785 | +233.5 % | 35.483.487 |
| CITADEL ADVISORS LLC | 1.743.915 | 319.571 | +22.4 % | 68.361.468 |
| ADAR1 Capital Management, LLC | 329.540 | 299.540 | +998.5 % | 12.917.968 |
| DIMENSIONAL FUND ADVISORS LP | 681.715 | 282.822 | +70.9 % | 26.714.134 |
| Avidity Partners Management LP | 400.000 | 259.700 | +185.1 % | 15.680.000 |
| GOLDMAN SACHS GROUP INC | 473.115 | 235.911 | +99.5 % | 18.546.108 |
| UBS Group AG | 283.544 | 225.676 | +390.0 % | 11.114.925 |
| Logos Global Management LP | 540.000 | 200.000 | +58.8 % | 21.168.000 |
Top 10 Verkäufer
| Fonds | Anteile | Δ Anteile | Δ % | Wert (USD) |
|---|---|---|---|---|
| Fairmount Funds Management LLC | 1.855.644 | -1.855.800 | -50.0 % | 72.741.245 |
| Janus Henderson Group Ltd. | 11.000 | -1.660.724 | -99.3 % | 431.200 |
| Venrock Adviser, LLC | 1.726.331 | -1.500.000 | -46.5 % | 67.672.175 |
| Commodore Capital LP | 3.275.000 | -1.417.809 | -30.2 % | 128.380.000 |
| Soleus Capital Management, L.P. | 230.869 | -794.131 | -77.5 % | 9.050.065 |
| Vestal Point Capital, LP | 3.250.000 | -580.000 | -15.1 % | 127.400.000 |
| Pictet Asset Management Holding SA | 929.544 | -373.691 | -28.7 % | 36.438.125 |
| FMR LLC | 6.829.246 | -278.389 | -3.9 % | 267.706.443 |
| Novo Holdings A/S | 1.280.000 | -200.000 | -13.5 % | 50.176.000 |
| Spruce Street Capital LP | 329.006 | -117.078 | -26.2 % | 12.897.035 |
Zusätzlich aktuell von 94 Mutual Funds/ETFs gehalten (N-PORT). Alle Fondsgesellschaften & ihre 4-Quartals-Bewegungen →
Aktivisten & Großaktionäre (13D/13G) ⓘ
| Datum | Investor | Typ | Anteil | Aktien | Δ | Zweck | Δ-Balken |
|---|---|---|---|---|---|---|---|
| 25.06.2026 | ORBIMED GENESIS GP LLC | Aktivist (13D/A) | 0,30 % | 219.405 | -0,05 pp | The Reporting Persons from time to time intend to review their investment in the Issuer … | |
| 25.06.2026 | ORBIMED CAPITAL GP VII LLC | Aktivist (13D/A) | 9,20 % | 6.555.102 | -1,38 pp | The Reporting Persons from time to time intend to review their investment in the Issuer … | |
| 25.06.2026 | ORBIMED ADVISORS LLC | Aktivist (13D/A) | 9,50 % | 6.774.507 | -1,43 pp | The Reporting Persons from time to time intend to review their investment in the Issuer … | |
| 25.06.2026 | ORBIMED CAPITAL LLC | Aktivist (13D/A) | Ausstieg | 0 | -0,04 pp | The Reporting Persons from time to time intend to review their investment in the Issuer … | |
| 22.06.2026 | Polar Capital Funds PLC - Biotechnology Fund (+2) | Passiv (13G/A) | 8,46 % | 5.056.807 | 0,00 pp | – | |
| 18.06.2026 | ORBIMED CAPITAL LLC | Aktivist (13D/A) | 0,04 % | 31.132 | -0,06 pp | The Reporting Persons from time to time intend to review their investment in the Issuer … | |
| 18.06.2026 | ORBIMED CAPITAL GP VII LLC | Aktivist (13D/A) | 10,58 % | 7.388.902 | -2,42 pp | The Reporting Persons from time to time intend to review their investment in the Issuer … | |
| 18.06.2026 | ORBIMED GENESIS GP LLC | Aktivist (13D/A) | 0,35 % | 245.728 | -0,05 pp | The Reporting Persons from time to time intend to review their investment in the Issuer … | |
| 18.06.2026 | ORBIMED ADVISORS LLC | Aktivist (13D/A) | 10,93 % | 7.634.630 | -2,47 pp | The Reporting Persons from time to time intend to review their investment in the Issuer … | |
| 15.05.2026 | Commodore Capital Master LP (+3) | Passiv (13G/A) | 7,70 % | 4.800.940 | -2,20 pp | – | |
| 15.05.2026 | Venrock Healthcare Capital Partners III, L.P. (+6) | Passiv (13G/A) | 2,80 % | 1.726.331 | -2,60 pp | – | |
| 15.05.2026 | Polar Capital Funds PLC - Biotechnology Fund (+2) | Passiv (13G/A) | 8,46 % | 5.056.807 | -0,01 pp | – | |
| 15.05.2026 | Polar Capital Funds PLC - Biotechnology Fund (+2) | Passiv (13G/A) | 8,47 % | 59.800.406 | +3,30 pp | – | |
| 15.05.2026 | Fairmount Healthcare Fund II L.P. (+3) | Passiv (13G/A) | 3,10 % | 1.855.644 | -3,20 pp | – | |
| 15.05.2026 | Vestal Point Capital, LP (+1) | Passiv (13G/A) | 5,40 % | 3.250.000 | -1,10 pp | – | |
| 17.02.2026 | Vestal Point Capital, LP (+1) | Passiv (13G) | 6,50 % | 3.830.000 | Neu | – | |
| 14.11.2025 | Venrock Healthcare Capital Partners III, L.P. (+6) | Passiv (13G/A) | 5,40 % | 3.226.331 | -1,80 pp | – | |
| 05.11.2025 | Abigail P. Johnson (+1) | Passiv (13G/A) | 13,30 % | 7.870.219 | Neu | – | |
| 14.08.2025 | Commodore Capital Master LP (+3) | Passiv (13G/A) | 9,90 % | 6.022.957 | Neu | – | |
| 14.08.2025 | Polar Capital Funds PLC - Biotechnology Fund (+2) | Passiv (13G) | 5,17 % | 2.536.881 | +0,28 pp | – | |
| 14.08.2025 | Fairmount Healthcare Fund II L.P. (+3) | Passiv (13G/A) | 6,30 % | 3.711.444 | -0,30 pp | – | |
| 17.07.2025 | BlackRock, Inc. | Passiv (13G/A) | 5,10 % | 2.941.395 | Neu | – | |
| 17.06.2025 | ORBIMED CAPITAL LLC | Aktivist (13D/A) | 0,10 % | 41.375 | Neu | The Reporting Persons from time to time intend to review their investment in the Issuer … | |
| 17.06.2025 | ORBIMED ADVISORS LLC | Aktivist (13D/A) | 13,40 % | 7.918.163 | Neu | The Reporting Persons from time to time intend to review their investment in the Issuer … | |
| 17.06.2025 | ORBIMED GENESIS GP LLC | Aktivist (13D/A) | 0,40 % | 254.814 | Neu | The Reporting Persons from time to time intend to review their investment in the Issuer … | |
| 17.06.2025 | ORBIMED CAPITAL GP VII LLC | Aktivist (13D/A) | 13,00 % | 7.663.349 | Neu | The Reporting Persons from time to time intend to review their investment in the Issuer … | |
| 14.02.2025 | Polar Capital Funds PLC - Biotechnology Fund (+2) | Passiv (13G/A) | 4,89 % | 2.389.668 | Neu | – | |
| 14.02.2025 | Fairmount Healthcare Fund II L.P. (+3) | Passiv (13G/A) | 6,60 % | 3.202.798 | -0,20 pp | – | |
| 14.11.2024 | Commodore (+1) | Passiv (13G/A) | 8,70 % | 4.100.000 | +1,70 pp | – | |
| 14.11.2024 | Venrock Healthcare Capital Partners EG, L.P. (+6) | Passiv (13G/A) | 8,50 % | 4.026.331 | Neu | – | |
| 14.11.2024 | RA Capital Healthcare Fund, L.P. (+3) | Passiv (13G/A) | 2,20 % | 1.061.233 | Neu | – | |
| 14.11.2024 | Citadel Securities Group LP (+2) | Passiv (13G/A) | 0,00 % | 6 | -0,50 pp | – | |
| 14.11.2024 | Citadel Advisors Holdings LP (+3) | Passiv (13G/A) | 3,70 % | 6 | +3,60 pp | – | |
| 14.11.2024 | Fairmount Healthcare Fund II L.P. (+3) | Passiv (13G/A) | 6,80 % | 3.202.798 | +1,60 pp | – | |
| 13.11.2024 | Polar Capital Holdings Plc (+1) | Passiv (13G) | 5,69 % | 2.687.797 | Neu | – | |
| 08.11.2024 | . BlackRock, Inc. | Passiv (13G) | 6,20 % | 2.936.642 | 0,00 pp | – | |
| 24.10.2024 | . BlackRock, Inc. | Passiv (13G) | 6,20 % | 2.936.642 | Neu | – | |
| 29.07.2024 | 5AM Opportunities I (GP), LLC (+1) | Aktivist (13D/A) | 0,80 % | 381.659 | -0,20 pp | – | |
| 29.07.2024 | 5AM Ventures VI, L.P. (+1) | Aktivist (13D/A) | 4,10 % | 1.922.673 | -1,00 pp | – | |
| 29.07.2024 | Andrew J. Schwab (+1) | Aktivist (13D/A) | 4,90 % | 2.304.332 | -1,20 pp | – |
Finanzkennzahlen (SEC XBRL) ⓘ
Währung:
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2026-03-31 | 10-Q | – | -23.627.000 $ | -0,38 $ | 464.852.000 $ | 453.365.000 $ |
| 2025-12-31 | 10-K | – | -103.694.000 $ | -1,83 $ | 476.168.000 $ | 459.600.000 $ |
| 2025-09-30 | 10-Q | – | -20.148.000 $ | -0,32 $ | 490.875.000 $ | 476.122.000 $ |
| 2025-06-30 | 10-Q | – | -25.335.000 $ | -0,49 $ | 503.887.000 $ | 488.472.000 $ |
| 2025-03-31 | 10-Q | – | -28.544.000 $ | -0,57 $ | 302.570.000 $ | 288.296.000 $ |
| 2024-12-31 | 10-K | – | -89.024.000 $ | -1,89 $ | 325.760.000 $ | 309.845.000 $ |
| 2024-09-30 | 10-Q | – | -23.156.000 $ | -0,48 $ | 305.430.000 $ | 288.403.000 $ |
| 2024-06-30 | 10-Q | – | -19.950.000 $ | -0,41 $ | 327.043.000 $ | 304.932.000 $ |
| 2024-03-31 | 10-Q | – | -22.738.000 $ | -0,54 $ | 342.777.000 $ | 317.712.000 $ |
| 2023-12-31 | 10-K | – | -71.584.000 $ | -2,01 $ | 271.867.000 $ | 245.906.000 $ |
| 2023-09-30 | 10-Q | – | -20.769.000 $ | -0,51 $ | 274.041.000 $ | 261.748.000 $ |
| 2023-06-30 | 10-Q | – | -16.721.000 $ | -0,41 $ | 288.501.000 $ | 278.994.000 $ |
| 2023-03-31 | 10-Q | – | -14.724.000 $ | -0,80 $ | 302.866.000 $ | 291.416.000 $ |
| 2022-12-31 | 10-K | – | -37.662.000 $ | -12,05 $ | 83.298.000 $ | -76.825.000 $ |
| 2022-09-30 | 10-Q | – | -10.554.000 $ | -3,27 $ | 59.104.000 $ | -68.097.000 $ |
| 2022-06-30 | 10-Q | – | -8.889.000 $ | -2,86 $ | 64.666.000 $ | -58.713.000 $ |
| 2022-03-31 | 10-Q | – | -8.669.000 $ | -3,01 $ | 81.602.000 $ | -50.610.000 $ |
| 2021-12-31 | 10-K | – | -51.384.000 $ | -2,37 $ | 93.646.000 $ | -42.887.000 $ |
| 2021-09-30 | 10-Q | – | -13.647.000 $ | -0,74 $ | 107.027.000 $ | 99.373.000 $ |
| 2021-06-30 | 10-Q | – | -13.161.000 $ | -0,74 $ | 72.468.000 $ | 64.967.000 $ |
Quartalsergebnisse (Earnings) ⓘ
| Quartal | Stichtag | Verkündet | Umsatz | EPS |
|---|---|---|---|---|
| Q1 2026 | 31.03.2026 | 07.05.2026 | – | -0,38 |
| Q3 2025 | 30.09.2025 | 12.11.2025 | – | -0,32 |
| Q2 2025 | 30.06.2025 | 13.08.2025 | – | -0,49 |
| Q1 2025 | 31.03.2025 | 14.05.2025 | – | -0,57 |
| Q3 2024 | 30.09.2024 | 13.11.2024 | – | -0,48 |
| Q2 2024 | 30.06.2024 | 13.08.2024 | – | -0,41 |
| Q1 2024 | 31.03.2024 | 14.05.2024 | – | -0,54 |
| Q3 2023 | 30.09.2023 | 09.11.2023 | – | -0,51 |
| Q2 2023 | 30.06.2023 | 10.08.2023 | – | -0,41 |
Einreichungs-Historie (10-K / 10-Q / 20-F / 6-K)
SEC-Einreichungs-Historie der letzten sechs Jahre (Datum = US-Kalendertag,
SEC/ET): Quartalsberichte (10-Q) und Jahresberichte (10-K); ausländische
Emittenten (ADR/Foreign Private Issuer) reichen stattdessen Jahresberichte
(20-F/40-F) und Zwischenmitteilungen (6-K) ein — dort liegt im SEC-Index
keine Berichtsperiode vor, Periode und Verzögerung bleiben leer. Die Spalte „Verzögerung" zeigt die
Tage zwischen Berichtsstichtag und tatsächlicher Einreichung.
Suffix /A kennzeichnet nachträgliche Berichtigungen.
| Eingereicht (US) | Form | Berichtsperiode | Verzögerung | |
|---|---|---|---|---|
| 07.05.2026 | 10-Q | 31.03.2026 | 37 Tage | SEC » |
| 03.03.2026 | 10-K | 31.12.2025 | 62 Tage | SEC » |
| 12.11.2025 | 10-Q | 30.09.2025 | 43 Tage | SEC » |
| 13.08.2025 | 10-Q | 30.06.2025 | 44 Tage | SEC » |
| 14.05.2025 | 10-Q | 31.03.2025 | 44 Tage | SEC » |
| 13.03.2025 | 10-K | 31.12.2024 | 72 Tage | SEC » |
| 13.11.2024 | 10-Q | 30.09.2024 | 44 Tage | SEC » |
| 13.08.2024 | 10-Q | 30.06.2024 | 44 Tage | SEC » |
| 14.05.2024 | 10-Q | 31.03.2024 | 44 Tage | SEC » |
| 14.03.2024 | 10-K | 31.12.2023 | 74 Tage | SEC » |
| 09.11.2023 | 10-Q | 30.09.2023 | 40 Tage | SEC » |
| 10.08.2023 | 10-Q | 30.06.2023 | 41 Tage | SEC » |
| 11.05.2023 | 10-Q | 31.03.2023 | 41 Tage | SEC » |
| 10.02.2023 | 10-K | 31.12.2022 | 41 Tage | SEC » |
| 25.10.2022 | 10-Q | 30.09.2022 | 25 Tage | SEC » |
| 03.08.2022 | 10-Q | 30.06.2022 | 34 Tage | SEC » |
| 06.05.2022 | 10-Q | 31.03.2022 | 36 Tage | SEC » |
| 15.03.2022 | 10-K | 31.12.2021 | 74 Tage | SEC » |
| 09.11.2021 | 10-Q | 30.09.2021 | 40 Tage | SEC » |
| 06.08.2021 | 10-Q | 30.06.2021 | 37 Tage | SEC » |
| 11.05.2021 | 10-Q | 31.03.2021 | 41 Tage | SEC » |
| 05.03.2021 | 10-K | 31.12.2020 | 64 Tage | SEC » |
| 05.11.2020 | 10-Q | 30.09.2020 | 36 Tage | SEC » |
| 14.08.2020 | 10-Q | 30.06.2020 | 45 Tage | SEC » |
Kapitalerhöhungen & Emissions-Historie
Emissions-Historie aus den finalen SEC-Prospekten: Börsengang (424B4) und Kapitalerhöhungen (424B5, Folge-/Sekundärplatzierungen). Volumen = Brutto-Erlös (bei Börsengängen zusätzlich der Ausgabepreis). Wiederholte Kapitalerhöhungen deuten auf Verwässerung der Altaktionäre hin.
| Datum (US) | Art | Volumen | |
|---|---|---|---|
| 12.06.2026 | Kapitalerhöhung | $376,0 Mio · $37,50/Aktie | SEC » |
| 11.06.2026 | Kapitalerhöhung | $250,0 Mio | SEC » |
| 16.06.2025 | Kapitalerhöhung | $165,0 Mio · $19,66/Aktie | SEC » |
| 13.06.2025 | Kapitalerhöhung | $200,0 Mio | SEC » |
| 06.07.2023 | Kapitalerhöhung | $200,0 Mio | SEC » |
| 15.03.2022 | Kapitalerhöhung | $11,0 Mio | SEC » |
| 14.07.2021 | Kapitalerhöhung | $50,0 Mio · $6,00/Aktie | SEC » |
| 13.07.2021 | Kapitalerhöhung | $50,0 Mio | SEC » |
Datum = US-Einreichungsdatum (SEC EDGAR, ET). Beträge in US-Dollar.
Proxy-/Governance-Filings
Proxy-Statements (SEC DEF-14A-Familie) der letzten sechs Jahre: reguläre HV-Einladungen zur Aktionärsversammlung, Aktivisten-Proxy-Fights (contested / Non-Management-Solicitation) und M&A-Abstimmungen.
| Datum (US) | Kategorie | HV-Termin (US) | Stichtag (US) | Form | |
|---|---|---|---|---|---|
| 27.04.2026 | HV-Einladung | — | — | DEFA14A | SEC » |
| 27.04.2026 | HV-Einladung | 09.06.2026 Jahres-HV | 10.04.2026 | DEF 14A | SEC » |
| 15.04.2026 | Vorläufig | — | — | PRE 14A | SEC » |
| 28.04.2025 | HV-Einladung | — | — | DEFA14A | SEC » |
| 28.04.2025 | HV-Einladung | 24.06.2025 Jahres-HV | 25.04.2025 | DEF 14A | SEC » |
| 26.04.2024 | HV-Einladung | — | — | DEFA14A | SEC » |
| 26.04.2024 | HV-Einladung | 18.06.2024 Jahres-HV | 19.04.2024 | DEF 14A | SEC » |
| 15.04.2024 | Vorläufig | — | — | PRE 14A | SEC » |
| 28.04.2023 | HV-Einladung | — | — | DEFA14A | SEC » |
| 28.04.2023 | HV-Einladung | 23.06.2023 Jahres-HV | 25.04.2023 | DEF 14A | SEC » |
| 19.10.2022 | HV-Einladung | — | — | DEFA14A | SEC » |
| 07.10.2022 | M&A-Abstimmung | 09.11.2022 a.o. HV | 05.10.2022 | DEFM14A | SEC » |
| 23.09.2022 | M&A-Abstimmung | — | — | PREM14A | SEC » |
| 07.09.2022 | HV-Einladung | — | — | DEFA14A | SEC » |
| 22.04.2022 | HV-Einladung | — | — | DEFA14A | SEC » |
| 22.04.2022 | HV-Einladung | 02.06.2022 Jahres-HV | 08.04.2022 | DEF 14A | SEC » |
| 18.05.2021 | HV-Einladung | — | — | DEFA14A | SEC » |
| 18.05.2021 | HV-Einladung | 29.06.2021 Jahres-HV | 06.05.2021 | DEF 14A | SEC » |
Datum = US-Einreichungsdatum (SEC EDGAR, ET). HV-Termin = Datum der Aktionärsversammlung, Stichtag (Record Date) = Nachweisstichtag für die Stimmberechtigung (aus dem Dokument extrahiert).
Übernahmen & Fusionen (M&A)
M&A-relevante SEC-Filings der letzten sechs Jahre: Übernahmeangebote (Tender Offers), Fusionen (425/S-4), Aktienrückkauf-Angebote (Self-Tender) und Going-Private-Transaktionen. Geführt nach dem einreichenden Emittenten.
| Datum (US) | Kategorie | Form | Deal-Konditionen | SEC |
|---|---|---|---|---|
| 22.02.2023 | Fusion | 425 | Ziel: Imara Inc. | SEC » |
| 13.02.2023 | Fusion | 425 | Ziel: Enliven Therapeutics, Inc. | SEC » |
| 09.01.2023 | Fusion | S-4/A | Ziel: Enliven · Umtausch 1,158 Akt./Ziel-Aktie | SEC » |
| 19.12.2022 | Fusion | S-4/A | Ziel: Enliven · Aktientausch · Umtausch 1,158 Akt./Ziel-Aktie | SEC » |
| 05.12.2022 | Fusion | 425 | Ziel: Enliven Therapeutics, Inc. | SEC » |
| 10.11.2022 | Fusion | S-4 | Ziel: Enliven · Aktientausch · Umtausch 1,158 Akt./Ziel-Aktie | SEC » |
| 14.10.2022 | Fusion | 425 | Ziel: Enliven Therapeutics, Inc. | SEC » |
| 13.10.2022 | Fusion | 425 | Ziel: Enliven · Aktientausch · Umtausch 1,08 Akt./Ziel-Aktie | SEC » |
Datum = US-Einreichungsdatum (SEC EDGAR, ET). Deal-Konditionen aus dem Dokument extrahiert (Tender: SC TO-T/-I/SC 14D9; Fusion: 425/S-4 — Gegenpartei + Umtauschverhältnis), ohne Gewähr — Original siehe SEC-Link.
Privatplatzierungen (Reg D)
Reg-D-Privatplatzierungen (Form D) der letzten sechs Jahre — SEC-befreite Kapitalaufnahmen ohne öffentliches Prospekt (z. B. PIPEs, Wandelanleihen an ausgewählte Investoren). Wiederholte Privatplatzierungen können auf laufenden Kapitalbedarf und Verwässerung der Altaktionäre hindeuten.
| Datum (US) | Art | Form | |
|---|---|---|---|
| 03.04.2024 | Privatplatzierung | D | SEC » |
Datum = US-Einreichungsdatum (SEC EDGAR, ET). Nur Metadaten — Emissions-Betrag und Investoren stehen im Dokument (SEC-Link).
Kritische 8-K Meldungen ⓘ
| Datum | Meldung | Tags | Schwere | Filing | Auszug |
|---|---|---|---|---|---|
| 01.03.2023 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | 1.01 of Form 8-K, the information contained in Item 5.02 is incorporated by reference herein. Item 2.01. Completion of… |
| 14.04.2022 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 25.10.2021 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
8-K-Ereignisse (KI)
🔒 Die vollständige KI-Einordnung je 8-K ist Teil des Kunden-Abos — freischalten.
| Datum | Ereignis | Sentiment | Materialität | Zusammenfassung | Filing |
|---|---|---|---|---|---|
| 12.06.2026 | Sonstiges | 0,00 | 15 | Item 7.01 Regulation FD Disclosure eingereicht. Substantiver Inhalt der Pressemitteilung (Exhibit 99.1) nicht bereitgestellt. | SEC |
| 11.06.2026 | Sonstiges | 0,00 | 30 | Unternehmen kündigte am 11. Juni 2026 aktualisierte Informationen an. Die Mitteilung im Reg FD-Disclosure ist unvollständig. | SEC |
| 07.05.2026 | Quartalszahlen | 0,00 | 50 | Enliven Therapeutics gab am 7. Mai 2026 die Finanzergebnisse für das Quartal zum 31. März 2026 bekannt. | SEC |
| 03.03.2026 | Quartalszahlen | 0,00 | 65 | Enliven Therapeutics kündigte die Finanzergebnisse für Q4 und das Geschäftsjahr 2025 an. | SEC |
Fail-to-Deliver (6 Monate) ⓘ
| Datum | FTD-Menge | Kurs | Wert (USD) |
|---|---|---|---|
| 2026-06-30 | 39.831 | 50,85 | 2.025.406 |
| 2026-06-18 | 146 | 44,86 | 6.550 |
| 2026-06-09 | 33.071 | 33,63 | 1.112.178 |
| 2026-06-05 | 31.591 | 35,49 | 1.121.165 |
| 2026-06-04 | 6.633 | 36,03 | 238.987 |
| 2026-06-02 | 14 | 37,51 | 525 |
| 2026-05-19 | 607 | 39,63 | 24.055 |
| 2026-05-14 | 10.394 | 43,56 | 452.763 |
| 2026-04-20 | 367 | 48,11 | 17.656 |
| 2026-04-13 | 55 | 45,32 | 2.493 |
| 2026-04-06 | 15.603 | 38,83 | 605.864 |
| 2026-04-02 | 15.707 | 37,79 | 593.568 |
| 2026-03-31 | 1.079 | 36,59 | 39.481 |
| 2026-03-30 | 18 | 38,83 | 699 |
| 2026-03-19 | 43 | 27,25 | 1.172 |
| 2026-03-10 | 3.406 | 29,73 | 101.260 |
| 2026-03-09 | 8.929 | 29,44 | 262.870 |
| 2026-03-06 | 2.455 | 29,29 | 71.907 |
| 2026-03-05 | 23.773 | 29,98 | 712.715 |
| 2026-03-04 | 30.016 | 28,75 | 862.960 |
| 2026-03-03 | 23.981 | 29,50 | 707.440 |
| 2026-02-27 | 659 | 29,62 | 19.520 |
| 2026-02-26 | 25 | 29,28 | 732 |
| 2026-02-23 | 890 | 26,02 | 23.158 |
| 2026-02-20 | 28.794 | 26,16 | 753.251 |
| 2026-02-18 | 59.914 | 26,13 | 1.565.553 |
| 2026-02-17 | 9.292 | 26,72 | 248.282 |
| 2026-02-13 | 2.384 | 27,16 | 64.749 |
| 2026-02-12 | 4 | 28,01 | 112 |
| 2026-02-11 | 2.252 | 27,93 | 62.898 |
| 2026-02-09 | 298 | 29,42 | 8.767 |
| 2026-02-06 | 5.098 | 26,99 | 137.595 |
| 2026-02-03 | 292 | 28,17 | 8.226 |
| 2026-02-02 | 292 | 26,45 | 7.723 |
| 2026-01-29 | 7.132 | 25,38 | 181.010 |
| 2026-01-23 | 47 | 27,03 | 1.270 |